PMC:7212965 / 40174-40557 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T88","span":{"begin":347,"end":354},"obj":"Body_part"}],"attributes":[{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma7148"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T68","span":{"begin":347,"end":354},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0000945"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T207","span":{"begin":266,"end":274},"obj":"Disease"}],"attributes":[{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T81","span":{"begin":3,"end":5},"obj":"Chemical"},{"id":"T82","span":{"begin":67,"end":72},"obj":"Chemical"},{"id":"T83","span":{"begin":156,"end":175},"obj":"Chemical"},{"id":"T84","span":{"begin":156,"end":165},"obj":"Chemical"},{"id":"T85","span":{"begin":166,"end":175},"obj":"Chemical"}],"attributes":[{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T180","span":{"begin":208,"end":214},"obj":"Phenotype"},{"id":"T181","span":{"begin":236,"end":244},"obj":"Phenotype"},{"id":"T182","span":{"begin":266,"end":274},"obj":"Phenotype"},{"id":"T183","span":{"begin":296,"end":316},"obj":"Phenotype"}],"attributes":[{"id":"A180","pred":"hp_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/HP_0002018"},{"id":"A181","pred":"hp_id","subj":"T181","obj":"http://purl.obolibrary.org/obo/HP_0002013"},{"id":"A182","pred":"hp_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A183","pred":"hp_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/HP_0002027"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1142","span":{"begin":3,"end":5},"obj":"Gene"},{"id":"1145","span":{"begin":137,"end":145},"obj":"Species"},{"id":"1150","span":{"begin":156,"end":175},"obj":"Chemical"},{"id":"1155","span":{"begin":208,"end":214},"obj":"Disease"},{"id":"1156","span":{"begin":236,"end":244},"obj":"Disease"},{"id":"1157","span":{"begin":266,"end":274},"obj":"Disease"},{"id":"1158","span":{"begin":347,"end":359},"obj":"Disease"}],"attributes":[{"id":"A1142","pred":"tao:has_database_id","subj":"1142","obj":"Gene:2770"},{"id":"A1145","pred":"tao:has_database_id","subj":"1145","obj":"Tax:9606"},{"id":"A1150","pred":"tao:has_database_id","subj":"1150","obj":"MESH:C558899"},{"id":"A1155","pred":"tao:has_database_id","subj":"1155","obj":"MESH:D009325"},{"id":"A1156","pred":"tao:has_database_id","subj":"1156","obj":"MESH:D014839"},{"id":"A1157","pred":"tao:has_database_id","subj":"1157","obj":"MESH:D003967"},{"id":"A1158","pred":"tao:has_database_id","subj":"1158","obj":"MESH:D063806"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s. GI adverse events were most common among those in the treatment group, and were the primary reason for medication discontinuation; of patients receiving lopinavir/ritonavir, there were 9.5% (9 of 99) with nausea, 6.3% (6 of 99) with vomiting, 4.2% (4 of 99) with diarrhea, 4.2% (4 of 99) with abdominal discomfort, 4.2% (4 of 99) with reported stomach ache, and 4.2% (4 of 99) wit"}